We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 05, 2022

Improved Outcomes With Higher Doses of Tisagenlecleucel in Relapsed/Refractory B-ALL

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium
Blood Adv 2022 Aug 08;[EPub Ahead of Print], H Stefanski, A Eaton, C Baggott, J Rossoff, MR Verneris, AK Keating, S Prabhu, HL Pacenta, CL Phillips, JA Talano, A Moskop, SP Margossian, GD Myers, NA Karras, PA Brown, M Qayed, ML Hermiston, P Satwani, C Krupski, R Wilcox, CA Rabik, VA Fabrizio, V Chinnabhandar, AY Goksenin, E Egeler, S Mavroukakis, KJ Curran, CL Mackall, TW Laetsch, LM Schultz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading